Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

Employees

Sector

Biotechnology & Medical Research

Calendar

09-22 Earnings release - Q2 2026

More about the company

Market Cap	11.68M 13.44M 10.87M 9.98M 18.85M 1.28B 19.15M 128M 50.31M 639M 50.47M 49.36M 2.14B	P/E 2024	-5.06x	P/E 2025	9.44x
Enterprise Value	9.97M 11.47M 9.28M 8.52M 16.1M 1.1B 16.35M 109M 42.95M 545M 43.09M 42.15M 1.83B	EV / Sales 2024	141x	EV / Sales 2025	281x
Free-Float	34.3%	Yield 2024 *	-	Yield 2025	-

07-14	Celyad Oncology SA announced that it expects to receive ?0.5 million in funding from Fortress Investment Group LLC	CI
07-14	Celyad Oncology to Raise Funds via Private Placement	MT
04-15	Prelude Therapeutics Incorporated Appoints Charles Morris as Chief Medical Officer, Effective April 20, 2026	CI
04-02	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-09-30	Celyad Oncology to Sell Belgian Research Facility for EUR3 Million	MT
25-09-29	Celyad Oncology announces research facility divestiture	RE
25-09-28	An undisclosed buyer agreed to acquire Research facility?s equipment and office furniture in Mont-Saint-Guibert, Belgium of Celyad Oncology SA for ?3 million.	CI
25-09-25	Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-26	Celyad Oncology Announces Discontinuation of R&D Activities and Workforce	CI
25-07-28	Celyad Oncology to Receive EUR1 Million Capital Injection from Shareholder	MT
25-07-27	Celyad Oncology SA announced that it expects to receive ?1 million in funding from CFIP CLYD (UK) Limited	CI
25-06-25	Celyad Oncology Begins Strategic Review Amid Limited Financial Runway	MT
25-06-24	Celyad Oncology Announces Strategic Review	CI

22-02-28	HC Wainwright Downgrades Celyad Oncology Neutral From Buy, Shares Plunge 12% at Midday Trading	MT
22-01-11	Wells Fargo Adjusts Celyad Oncology's Price Target to $11 from $20, Keeps Overweight Rating	MT
21-08-06	CELYAD ONCOLOGY : HC Wainwright Adjusts Celyad Oncology's Price Target to $15 From $17, Maintains Buy Rating	MT
21-03-26	CELYAD ONCOLOGY : JonesTrading Downgrades Celyad Oncology to Hold from Buy	MT
20-12-08	CELYAD ONCOLOGY : HC Wainwright Adjusts Celyad Oncology's Price Target to $18 From $22, Keeps Buy Rating	MT

07-28	Celyad Oncology : Publication of a transparency notification received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)	PU
07-14	Celyad Oncology : Announces €500,000 Private Placement	PU
05-20	Celyad Oncology : AGM Minutes - informal translation EN	PU
04-02	Celyad Oncology : reports full year 2025 financial results and business highlights	PU
25-09-29	Celyad Oncology : Announces Research Facility Divestiture	PU

07-28	Celyad Oncology : Publication d’une notification de transparence reçue de Tolefi SA (Article 14§1 de la Loi du 2 Mai 2007)
07-18	Rustige start cijferseizoen in Brussel
07-14	Celyad kondigt private plaatsing van 500.000 euro aan
05-20	Celyad Oncology : AGO Procès Verbal - version FR
04-17	Celyad Oncology : Rapport Annuel 2025 FR

Celyad SA Stock Other OTC

Stocks

CLYYF

BE0974260896

Biotechnology & Medical Research

Valuation: Celyad SA

Latest news : Celyad SA

Analysts' recommendations: Celyad SA

Press Releases: Celyad SA

News in other languages: Celyad SA

Quotes and Performance

Managers and Directors: Celyad SA

Other Biotechnology & Medical Research

Financials

Company Profile

Manager	Title	Age	Since
David Georges DFI	Director of Finance/CFO	-	2018-12-31
An Phan LAW	General Counsel	51	2021-08-31

Director	Title	Age	Since
Michel Lussier CHM	Chairman	69	2007-07-23
Serge Goblet BRD	Director/Board Member	-	2007-12-31
Hilde Windels CHM	Chairman	61	2022-06-22

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELYAD SA	-25.25%	-.--%	-	-	13.44M
LONZA GROUP AG	-1.40%	+2.59%	-1.71%	+12.94%	48.53B
REVOLUTION MEDICINES, INC.	-2.41%	-0.90%	+411.96%	+472.09%	39.87B
IQVIA HOLDINGS INC.	-1.16%	+12.96%	+28.81%	+7.27%	38.68B
BEONE MEDICINES AG	-1.88%	-3.03%	+5.69%	+66.52%	35.13B
CELLTRION, INC.	-1.74%	+5.12%	+14.44%	+44.64%	29.79B
MEDPACE HOLDINGS, INC.	-0.21%	-4.04%	+36.40%	+126.06%	16.11B
ASCENDIS PHARMA A/S	-2.85%	-3.92%	-	-	16.08B
EUROFINS SCIENTIFIC SE	-0.64%	+2.65%	+3.40%	+14.79%	13.61B
ICON PUBLIC LIMITED COMPANY	-1.19%	-1.32%	-1.73%	-34.97%	12.62B
Average	-3.87%	+1.05%	+62.16%	+88.67%	27.82B
Weighted average by Cap.	-1.60%	+2.03%	+79.78%	+107.48%

	2024	2025
Net sales	186K 214K 173K 159K 300K 20.43M 305K 2.04M 801K 10.17M 804K 786K 34.1M	21K 24.16K 19.55K 17.95K 33.89K 2.31M 34.41K 230K 90.43K 1.15M 90.73K 88.73K 3.85M
Net income	-5.82M -6.7M -5.42M -4.98M -9.4M -640M -9.54M -63.9M -25.08M -318M -25.16M -24.61M -1.07B	830K 955K 773K 709K 1.34M 91.14M 1.36M 9.11M 3.57M 45.38M 3.59M 3.51M 152M
Net Debt	-3.3M -3.79M -3.07M -2.82M -5.32M -362M -5.4M -36.15M -14.19M -180M -14.24M -13.92M -604M	-1.71M -1.96M -1.59M -1.46M -2.76M -188M -2.8M -18.74M -7.35M -93.38M -7.38M -7.22M -313M